The increase of left ventricular mass represents the structural
|
|
- Clare Norman
- 5 years ago
- Views:
Transcription
1 17 -Estradiol Attenuates the Development of Pressure-Overload Hypertrophy Martin van Eickels, MD; Christian Grohé, MD; Jack P.M. Cleutjens, PhD; Ben J. Janssen, PhD; Hein J.J. Wellens, MD; Pieter A. Doevendans, MD Background Cardiac hypertrophy is an independent risk factor for cardiovascular morbidity and mortality in men and in women. Epidemiological studies indicate that estrogen replacement therapy is cardioprotective; the mechanisms involved in this process, however, are poorly understood. We therefore studied the effect of 17 -estradiol (E 2 ) on the development of pressure-overload hypertrophy. Methods and Results Ovariectomized mice receiving E 2 or placebo underwent transverse aortic constriction (TAC) or sham operation. TAC led to a significant increase in ventricular mass compared with sham operation. E 2 treatment reduced cardiac hypertrophy by 31% and 26% compared with placebo 4 and 8 weeks after TAC, whereas it had no effect on the degree of pressure overload, as determined by hemodynamic measurements. Furthermore, E 2 blocked the increased phosphorylation of p38-mitogen activated protein kinase (MAPK) observed in the placebo-treated animals with TAC. No differences were observed in the phosphorylation of extracellular signal regulated kinase (ERK) 1/2 and c-jun N-terminal kinase (JNK) 1/2 between the groups. E 2 had no effect on the expression of angiotensin-converting enzyme (ACE) or the angiotensin II type 1 receptor. Ventricular atrial natriuretic peptide (ANP) expression was detected only in the animals with TAC. Compared with placebo, E 2 treatment led to an increased expression of ANP in animals with pressure overload. Conclusions Here, we show that E 2 attenuates the hypertrophic response to pressure overload in mice. This observation demonstrates that hormone replacement therapy with E 2 has direct effects on the heart and may be beneficial in the treatment of postmenopausal women to reduce cardiac hypertrophy. (Circulation. 2001;104: ) Key Words: hormones hypertrophy myocardium sex The increase of left ventricular mass represents the structural mechanism of adaptation of the heart in response to pressure overload. The resulting left ventricular hypertrophy is an important negative predictor of cardiac morbidity and mortality and displays significant sex-based differences. 1,2 Estrogen is known to have multiple protective effects on the cardiovascular system. 3 The role of estrogen in the development of cardiac hypertrophy, however, is poorly understood. See p 1333 We have shown previously that cardiac myocytes and cardiac fibroblasts contain both known estrogen receptor isoforms, called and. 4 Via these receptors, estrogen can regulate the cardiac expression of endothelial and inducible NO synthase and connexin Estrogen also modulates the activity of the mitogen-activated protein kinase (MAPK) pathways in cardiac myocytes. 6 The MAPK signaling pathways consist of a sequence of successively acting kinases that ultimately result in the dual phosphorylation and activation of effector kinases such as p38-mapks, c-jun N-terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs), which subsequently phosphorylate a large array of targets, leading to altered gene expression patterns. 7 These signaling cascades play an important role in the initiation of cardiac hypertrophy and in the development of heart failure Furthermore, we have shown previously that estrogen downregulates the activity of the renin-angiotensin system in the vasculature of normotensive and of hypertensive rats. 11,12 The inhibition of the renin-angiotensin system has an antihypertrophic effect and is used widely in the therapy of patients with cardiac hypertrophy. 13 In addition, it is known that estrogen can increase the expression of atrial natriuretic peptide (ANP). 14,15 ANP has long been known to be a marker of cardiac hypertrophy. More recent studies, however, have suggested that ANP possesses antihypertrophic properties. 16,17 Taken together, these data led us to the hypothesis that estrogen may modulate the development of cardiac hypertrophy. We therefore studied the effects of 17 -estradiol (E 2 ), the predominant estrogen in premenopausal women, on the Received April 9, 2001; revision received June 4, 2001; accepted June 5, From the Cardiovascular Research Institute Maastricht, University of Maastricht (M.v.E., J.P.M.C., B.J.J.), and the Department of Cardiology, Academisch Ziekenhuis Maastricht (H.J.J.W., P.A.D.), Maastricht, Netherlands; and the Medizinische Universitäts-Poliklinik, Bonn, Germany (C.G.). Correspondence to Martin van Eickels, MD, Division of Cardiology, Department of Internal Medicine II, University of Bonn, Sigmund Freud Straße 25, Bonn, Germany. mvaneickels@lifespan.org or vaneickels@altavista.com 2001 American Heart Association, Inc. Circulation is available at
2 1420 Circulation September 18, 2001 Effects of TAC and E 2 Treatment on Body and Organ Weights, Blood Pressure, and Myocyte Size Sham TAC Placebo E 2 Placebo E 2 4 Weeks 8 Weeks 4 Weeks 8 Weeks 4 Weeks 8 Weeks 4 Weeks 8 Weeks BW, g VW, mg * * 174 6* 159 8* VW/TL, mg/mm * * * * Lung weight, mg * * Uterus weight, mg P sys,mmhg * 115 8* 118 3* 115 9* Myocyte CSA, m * 199 9* BW indicates body weight; VW, ventricular weight; TL, tibial length; P sys, prestenotic systolic pressure; and CSA, myocyte cross-sectional area. All values are mean SEM. Four weeks, n 7; 8 weeks, n 6. *P 0.05 for TAC vs sham, P 0.05 for E 2 vs placebo. development of pressure-overload hypertrophy and the activation of the pathways mentioned above. Methods Animals Ten-week-old female C57BL/6 mice were housed under standard conditions. Animals were anesthetized with ketamine (100 mg/kg body weight [BW] IP) and xylazine (10 mg/kg BW IP) for ovariectomy, pellet placement, and transverse aortic constriction (TAC). The study was approved by the animal ethics committee of the University of Maastricht. Estrogen Replacement One week after ovariectomy, a 60-day-release pellet containing 0.18 mg E 2 or placebo was implanted subcutaneously. E 2 serum levels were measured with a radioimmunoassay (DPC Biermann) in a subset of animals. To measure the magnitude of proliferation of cardiac cells, a subgroup of animals with pressure overload received bromodeoxyuridine (BrdU) (2.5 mg per 21-day-release pellet) for the last 14 days of the study period. All pellets were purchased from Innovative Research of America. Surgical Procedures and Hemodynamics One week after the pharmacological intervention, TAC was performed, as described previously. 18 Sham-operated animals underwent an identical operation without placement of the constricting suture. There was no difference in the mortality between the E 2 - and the placebo-treated animals. Four and 8 weeks (n 7 and n 6 per group) after TAC or the sham procedure, animals were anesthetized with pentobarbital (100 mg/kg BW IP). Pressure-transducing catheters were introduced into the right and the left carotid arteries, and systolic pressure before and after the stenosis was measured as described previously. 19 Tissue Preparation and Histology Hearts were arrested in diastole with CdCl 2 (0.1 mol/l IV). For morphometric analysis, hearts were fixed in 10% formalin and embedded in paraffin as described previously. 20 For protein extraction, hearts were excised, washed in ice-cold PBS, and frozen. All external fluid was completely removed before the organs were weighed. Transverse sections of the heart were stained with hematoxylin and eosin, picrosirius red, modified Azan, or anti-brdu antibodies. The analysis of the collagen content was performed with a computerized morphometry system as described previously. 20 Cross-sectional areas of 50 (sham) or 100 (TAC) myocytes in which the centrally located nucleus and a clear staining of the cell borders could be visualized were measured in the transversely cut papillary muscles of each animal. Immunoblot Analysis Total heart lysates (40 g/lane) were analyzed by standard immunoblotting procedures as described previously. 5,6,21 24 Equal loading was checked by stripping and reprobing the membrane with troponin C. The following primary antibodies were used: ACE (BMA Biomedicals AG); ANP (Phoenix Pharmaceuticals Inc); angiotensin type 1 receptor (AT 1 R), ERK1/2, JNK, MKP1, p38-mapk, phospho-jnk (Thr183/Tyr185), and troponin C (Santa Cruz Biotechnology Inc); and phospho-erk1/2 (Thr202/Tyr204) and phospho-p-38 MAPK (Thr180/Tyr182) (New England Biolabs GmbH). Detection was performed with the enhanced chemiluminescence technique after incubation with a suitable secondary antibody coupled to horseradish peroxidase (ECL; Amersham Pharmacia Biotech). A computerized image acquisition system (Alpha Innotech Corp) was used for densitometric analysis. Statistical Analysis Data are shown as mean SEM. Means were compared by ANOVA, followed by Bonferroni s test for multiple comparisons. Differences were considered significant at P Results Estrogen replacement led to a reconstitution of physiological estrogen levels (sham pg/ml, TAC pg/ml, n 5 per group). All measured E 2 levels in animals receiving placebo were 5 pg/ml. Uterus weight was measured to demonstrate the effectiveness of ovariectomy and E 2 substitution in all animals (Table). TAC led to a significant increase in ventricular mass 4 and 8 weeks after the intervention. The degree of ventricular hypertrophy was significantly lower in E 2 -treated than placebo-treated animals with pressure overload (Figure 1A). Compared with placebo, E 2 treatment led to a significant reduction of the ventricular weight (VW), the VW/BW ratio, and the VW/tibial length ratio in animals with pressure overload (Figure 2 and Table). No differences were observed between the E 2 - and the placebo-treated animals that were sham-operated (Figure 2 and Table). The lung weight was increased in the animals with TAC; however, this increase reached statistical significance only in the placebo-treated animals (Table). There were no differences in BW between the groups (Table). Because E 2 can alter blood pressure, we tested whether the observed antihypertrophic effect of estrogen could be medi-
3 van Eickels et al Estrogen and Pressure-Overload Hypertrophy 1421 Figure 2. A, Ventricular weight (VW)/BW ratios from animals with (TAC) and without (sham) pressure overload that were treated with either E 2 or placebo (P) 4 and 8 weeks after intervention. B, Systolic pressure gradients across stenosis 4 and 8 weeks after intervention: 4 weeks, n 7 per group; 8 weeks, n 6 per group. *P 0.05 for TAC vs sham, P 0.05 for E 2 vs placebo. Figure 1. A, Transverse sections of hearts stained with hematoxylin-eosin from animals with (TAC) and without (sham) pressure overload that were treated with either E 2 or placebo 4 weeks after TAC (bars 1 mm). B, Picrosirius red stained anterior septal sections from animals with (TAC) and without (sham) pressure overload that were treated with either E 2 or placebo 4 weeks after TAC to demonstrate interstitial fibrosis (bars 100 m). ated by a change in the degree of pressure overload. In our model of TAC, E 2 had no influence on the degree of pressure overload as determined by the pressure gradient or the prestenotic pressure (Figure 2B). Histological analysis revealed that pressure overload led to progressive cardiac fibrosis (Figure 1B). No differences in collagen content (E % and placebo %) or proliferation of interstitial cells, measured by BrdU labeling (E % and placebo %), however, were observed in the animals with ventricular hypertrophy. TAC led to a significant increase of myocyte size, as determined by myocyte cross-sectional area. This increase was significantly attenuated by treatment with E 2 compared with placebo (Table). To further elucidate the mechanism involved in the observed antihypertrophic effect of estrogen, we studied pathways involved in the development and progression of cardiac hypertrophy, which also have been shown to be regulated by E 2. Immunoblot analysis revealed that E 2 blocked the increased phosphorylation of p38-mapk in ovariectomized animals with pressure-overload hypertrophy, whereas it exerted no effect in sham-operated animals (Figures 3A and 4A). No differences could be observed between the study groups with regard to the phosphorylation level of ERK1/2 and JNK (Figure 3A). In the sham-operated animals, the levels of AT 1 R expression were slightly lower in E 2 -treated animals; however, this difference did not reach statistical significance. In the hypertrophied hearts, no differences in the expression levels of AT 1 R or ACE were detected between the E 2 - and the placebo-treated animals (Figure 3B). Compared with placebo, E 2 treatment led to an increase in ANP expression in the hypertrophied ventricles. No significant levels of ANP were detectable in the ventricles of shamoperated animals (Figures 3C and 4B). Discussion Here, we show for the first time that hormone replacement therapy with physiological doses of E 2 can attenuate the development of pressure-overload hypertrophy. In contrast to a previous study in spontaneously hypertensive rats, the antihypertrophic effect observed in our study was not mediated by the blood pressure lowering effect of E We did not observe E 2 -associated differences in cardiac fibrosis and cell proliferation in the heart. In fact, myocyte cross-sectional area was attenuated by estrogen treatment compared with placebo. Therefore, our study supports the hypothesis that E 2 has direct effects on cardiac myocytes and the heart. To further elucidate the mechanisms involved, we studied the activation of MAPK 7 9,27 and the expression of ACE, AT 1 R, 13,15 and ANP, 14,17 all of which have been shown to
4 1422 Circulation September 18, 2001 Figure 3. Ventricular expression of (A) phospho-p38-mapk, p38-mapk, phospho-erk1/2, ERK1/2, phospho-jnk, and JNK; (B) AT 1 R and ACE; and (C) ANP in animals with (TAC) and without (sham) pressure overload that were treated with either E 2 or placebo (P), as determined by immunoblot analysis. play important roles in the development and progression of cardiac hypertrophy and are estrogen responsive. A previous study suggested that the activation of p38- MAPK is important for the maintenance of the hypertrophic response over a longer period of time. 27 Therefore, the inhibition of the p38-mapk phosphorylation by E 2 treatment may represent one of the mechanisms by which E 2 exerts its antihypertrophic effect in our model of pressure overload. ERK1/2 and JNK were not activated in all the animals with pressure overload, possibly because these pathways may be more important in the induction of the hypertrophic response and have returned to baseline after 4 weeks. Inhibition of the renin-angiotensin system plays an important role in the development of cardiac hypertrophy. On the basis of our previous findings that E 2 reduces the expression of the AT 1 R, 11,12 we hypothesized that a similar mechanism could be involved in the observed antihypertrophic effect of E 2. No such differences were observed, however, in the hypertrophied hearts. Recent studies have identified the antihypertrophic properties of ANP. 16,17 Furthermore, it has been shown previously that E 2 increases the expression of ANP. 14,28 In concordance with these results, E 2 led to an increase in ANP expression in the ventricles of animals with pressure overload compared with placebo. These findings suggest that the antihypertrophic effect of E 2 may be mediated by the increased expression of ANP. The development of cardiac hypertrophy is a complex process involving signal integration of multiple pathways. 7,29 Therefore, it may well be that the observed antihypertrophic effect of E 2 is mediated by the modulation of not one but several of these pathways. To further elucidate the mechanisms involved in E 2 s antihypertrophic effects, it will be necessary to identify the essential signaling molecules in- Figure 4. Densitometric analysis of phospho-p38-mapk/p38- MAPK (A) and ANP (B) immunoblots. n 6 per group. *P 0.05 for TAC vs sham, P 0.05 for E 2 vs placebo. volved in the development of cardiac hypertrophy, their time course of activation, and the cross talk between them. Overall, our results suggest that the lack of estrogen may be responsible for the increase in ventricular hypertrophy observed in postmenopausal women. Furthermore, these findings may constitute a novel approach in the treatment of postmenopausal women at risk of developing cardiac hypertrophy. Acknowledgments This work was supported by the Deutsche Forschungsgemeinschaft (Gr729/8 1), BONFOR (O708), the Cardiovascular Biology Foundation in Delft, and the Bekales Foundation. Dr van Eickels received a postdoctoral fellowship from the German Academic Exchange Service (DAAD). We thank Richard H. Karas, MD, PhD, for his valuable comments, Peter Leenders and Jacques Debets for expert assistance with the animal surgery, and Hanne Bock for expert technical assistance with the immunoblots. References 1. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72: Liao Y, Cooper RS, Mensah GA, et al. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 1995; 92: Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340: Grohé C, Kahlert S, Löbbert K, et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997;416: Nüdling S, Kahlert S, Löbbert K, et al. 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res. 1999;43: Nüdling S, Kahlert S, Löbbert K, et al. Differential effects of 17betaestradiol on mitogen-activated protein kinase pathways in rat cardiomyocytes. FEBS Lett. 1999;454: Sugden PH, Clerk A. Stress-responsive mitogen-activated protein kinases (c-jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83: Bueno OF, De Windt LJ, Lim HW, et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res. 2001;88:88 96.
5 van Eickels et al Estrogen and Pressure-Overload Hypertrophy Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000;19: Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation. 2001;103: Nickenig G, Bäumer AT, Grohé C, et al. Estrogen modulates AT 1 receptor gene expression in vitro and in vivo. Circulation. 1998;97: Wassmann S, Bäumer AT, Strehlow K, et al. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation. 2001;103: Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275: Deng Y, Kaufman S. The influence of reproductive hormones on ANF release by rat atria. Life Sci. 1993;53: Potvin W, Varma DR. Down-regulation of myometrial atrial natriuretic factor receptors by progesterone and pregnancy and up-regulation by oestrogen in rats. J Endocrinol. 1991;131: Horio T, Nishikimi T, Yoshihara F, et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 2000;35: Masciotra S, Picard S, Deschepper CF. Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. Circ Res. 1999;84: Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88: Doevendans PA, Daemen MJ, de Muinck ED, et al. Cardiovascular phenotyping in mice. Cardiovasc Res. 1998;39: Lutgens E, Daemen MJ, de Muinck ED, et al. Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc Res. 1999;41: Kahlert S, Nüdling S, van Eickels M, et al. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 2000;275: van Eickels M, Vetter H, Grohé C. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-i (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol. 2000;131: van Eickels M, Grohé C, Löbbert K, et al. Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn Schmiedebergs Arch Pharmacol. 1999;359: Rubattu S, Lee-Kirsch MA, DePaolis P, et al. Altered structure, regulation, and function of the gene encoding the atrial natriuretic peptide in the stroke-prone spontaneously hypertensive rat. Circ Res. 1999;85: Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47: Sharkey LC, Holycross BJ, Park S, et al. Effect of ovariectomy and estrogen replacement on cardiovascular disease in heart failure-prone SHHF/Mcc- fa cp rats. J Mol Cell Cardiol. 1999;31: Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol. 1998;142: Hong M, Yan Q, Tao B, et al. Estradiol, progesterone and testosterone exposures affect the atrial natriuretic peptide gene expression in vivo in rats. Biol Chem Hoppe Seyler. 1992;373: Homcy CJ. Signaling hypertrophy: how many switches, how many wires. Circulation. 1998;97:
In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension
In the name of GOD Animal models of cardiovascular diseases: myocardial infarction & hypertension 44 Presentation outline: Cardiovascular diseases Acute myocardial infarction Animal models for myocardial
More informationJ Jpn Coll Angiol, 2009, 49:
Online publication October 6, 2009 48 2 20 J Jpn Coll Angiol, 2009, 49: 293 297 atrial natriuretic peptide, brain natriuretic peptide, guanylyl cyclase-a receptor, cardiac remodeling, cardiac hypertrophy
More informationAT1 RECEPTOR BLOCKADE ATTENUATES INSULIN RESISTANCE AND MYOCARDIAL REMODELING IN RATS WITH DIET-INDUCED OBESITY
AT1 RECEPTOR BLOCKADE ATTENUATES INSULIN RESISTANCE AND MYOCARDIAL REMODELING IN RATS WITH DIET-INDUCED OBESITY SA Oliveira Jr, MP Okoshi, PF Martinez, DM Guizoni, BP Torres, M Dal Pai-Silva, K Okoshi,
More informationExercise in Adverse Cardiac Remodeling: of Mice and Men
Exercise in Adverse Cardiac Remodeling: of Mice and Men 17-01-2013 Dirk J Duncker Experimental Cardiology, Cardiology, Thoraxcenter Cardiovascular Research Institute COEUR Erasmus MC, University Medical
More informationSupporting Information
Supporting Information Muraski et al. 10.1073/pnas.0709135105 SI Text Generation of Transgenic Animals. Pim-WT and Pim-DN cdnas were subcloned NheI/SmaI from pegfp-c1 Pim-1 and pegfp-c1 Pim-DN plasmids
More informationThe mammalian heart elicits hypertrophy in response to
17 -Estradiol Antagonizes Cardiomyocyte Hypertrophy by Autocrine/Paracrine Stimulation of a Guanylyl Cyclase A Receptor Cyclic Guanosine Monophosphate Dependent Protein Kinase Pathway Fawzi A. Babiker,
More informationhemodynamic stress. A. Echocardiographic quantification of cardiac dimensions and function in
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1. Fbn1 C1039G/+ hearts display normal cardiac function in the absence of hemodynamic stress. A. Echocardiographic quantification of cardiac dimensions and
More informationIntermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction
Related Commentary, page 1467 Research article Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction Cinzia Perrino, 1 Sathyamangla V. Naga Prasad,
More informationIn Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison
In Vivo Animal Models of Heart Disease Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison Why Animal Models of Disease? Heart Failure (HF) Leading cause of morbidity and mortality
More informationSupplemental Figure I
Supplemental Figure I Kl ( mmol/l)-induced Force orta M (mn) 1 (mn) 1 Supplemental Figure I. Kl-induced contractions. and, Kl ( mmol/l)-induced contractions of the aorta () and those of mesenteric arteries
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationEffects of sitagliptin on cardiac metabolism in mice
Effects of sitagliptin on cardiac metabolism in mice M. Lenski, J.-C. Reil, M. Böhm, U. Laufs Saarland University Hospital Department of Internal Medicine III, Cardiology Homburg - Germany Disclosures
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST A potential anti-hypertrophic agent Riham Abouleisa Cardiac hypertrophy is a compensatory response to maintain function during increased stress. A sustained hypertrophic
More informationProtection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein
Protection against doxorubicin-induced myocardial dysfunction in mice by cardiac-specific expression of carboxyl terminus of hsp70-interacting protein Lei Wang 1, Tian-Peng Zhang 1, Yuan Zhang 2, Hai-Lian
More informationC57BL/6 Mice are More Appropriate. than BALB/C Mice in Inducing Dilated Cardiomyopathy with Short-Term Doxorubicin Treatment
Original Article C57BL/6 Mice are More Appropriate Acta Cardiol Sin 2012;28:236 240 Heart Failure & Cardiomyopathy C57BL/6 Mice are More Appropriate than BALB/C Mice in Inducing Dilated Cardiomyopathy
More information1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism
Pathobiology of Heart Failure Molecular and Cellular Mechanism Jonathan Leor Neufeld Cardiac Research Institute Tel-Aviv University Sheba Medical Center, Tel-Hashomer שאלה 1 התא הנפוץ ביותר (75%~) בלב
More informationrenoprotection therapy goals 208, 209
Subject Index Aldosterone, plasminogen activator inhibitor-1 induction 163, 164, 168 Aminopeptidases angiotensin II processing 64 66, 214 diabetic expression 214, 215 Angiotensin I intrarenal compartmentalization
More informationΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ
ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has several regulatory
More informationRemodeling the failing heart: : the biology and future treatment options
Remodeling the failing heart: : the biology and future treatment options J-L Balligand (UCL-Brussels, BE) jl.balligand@uclouvain.be Myocardial remodeling: definitions phenotypic plasticity : remodeling
More informationSupplementary Material
Supplementary Material Induction of myocardial infarction Mice were anesthetized by intraperitoneal injection of pentobarbital (7 mg/kg). In the supine position, endotracheal intubation was performed.
More informationProtein kinase A mediated stimulation of activating transcription factor 3 by hypertrophic stimuli in cardiomyocytes
Protein kinase A mediated stimulation of activating transcription factor 3 by hypertrophic stimuli in cardiomyocytes Elina Koivisto, MD, PhD Institute of Biomedicine, Department of Pharmacology and Toxicology
More informationIn vivo bromodeoxyuridine (BrdU) incorporation was performed to analyze cell
Supplementary Methods BrdU incorporation in vivo In vivo bromodeoxyuridine (BrdU) incorporation was performed to analyze cell proliferation in the heart. Mice were subjected to LI-TAC, and 5 days later
More informationFull Record.
第 1 頁, 共 2 頁 Full Record Record 1 of 6 (Set #2) Title: Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes Author(s): Shyu KG, Ko WH,
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA 2
Evidence for angiotensin II type 2 receptor mediated cardiac myocyte enlargement during in vivo pressure overload Rapid PUBLICATION Takaaki Senbonmatsu, 1 Sahoko Ichihara, 1 Edward Price, Jr., 1 F. Andrew
More informationExtracellular matrix Basic and translational science: Highlights of the congress
Extracellular matrix Basic and translational science: Highlights of the congress Stephane Heymans, Maastricht University Medical Centre, CARIM, Netherlands Speaker The extracellular matrix modulates cardiac
More informationFas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload
Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload Cornel Badorff, 1 Hartmut Ruetten, 2 Sven Mueller, 1 Meike Stahmer, 1 Doris Gehring,
More informationSupplementary Figure 1:
Supplementary Figure 1: (A) Whole aortic cross-sections stained with Hematoxylin and Eosin (H&E), 7 days after porcine-pancreatic-elastase (PPE)-induced AAA compared to untreated, healthy control aortas
More informationAccumulating in vivo evidence indicates that angiotensin
Important Role of Angiotensin II Mediated c-jun NH 2 -Terminal Kinase Activation in Cardiac Hypertrophy in Hypertensive Rats Yasukatsu Izumi, Shokei Kim, Yumei Zhan, Masashi Namba, Hideo Yasumoto, Hiroshi
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationSUPPLEMENTAL MATERIAL. Supplementary Methods
SUPPLEMENTAL MATERIAL Supplementary Methods Culture of cardiomyocytes, fibroblasts and cardiac microvascular endothelial cells The isolation and culturing of neonatal rat ventricular cardiomyocytes was
More informationElectrical Stimulation Control Nerve Regeneration via the p38 Mitogen-activated Protein Kinase and CREB
Electrical Stimulation Control Nerve Regeneration via the p38 Mitogen-activated Protein Kinase and CREB Kenji Kawamura, Yoshio Kano. Kibi International University, Takahashi-city, Japan. Disclosures: K.
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationUncovering the mechanisms of wound healing and fibrosis
Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationSex-specific differences in ventricular expression and function of parathyroid hormone-related peptide $
Cardiovascular Research 61 (2004) 307 316 www.elsevier.com/locate/cardiores Sex-specific differences in ventricular expression and function of parathyroid hormone-related peptide $ Christian Grohé a, Martin
More informationParacrine Mechanisms in Adult Stem Cell Signaling and Therapy
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy Massimiliano Gnecchi, Zhiping Zhang, Aiguo Ni, Victor J. Dzau Circulation Research 2008 Nov 21;103(11):1204-19 Introduction(1) After AMI all
More informationDr. Khairy Abdel Dayem. Professor of Cardiology Ain-Shams University
Dr. Khairy Abdel Dayem Professor of Cardiology Ain-Shams University RALES Randomized Aldactone Evaluation Study 1. NEJM 1999 2. Bertram Pitt 3. 1660 Class III and IV HF patients 4. EF 35% 5. 841 placebo
More informationEffects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats
Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats Y. Zhu 1, H.-S. Wang 1, X.-M. Li 1 and C. Qu 2 1 Department of Cardiac Surgery, General
More informationMEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1 L613V mutation
Related Commentary, page 844 Research article MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1 L613V mutation Xue Wu, 1,2 Jeremy Simpson,
More informationEstrogen receptor- mediates male-female differences in the development of pressure overload hypertrophy
Am J Physiol Heart Circ Physiol 288: H469 H476, 2005. First published September 16, 2004; doi:10.1152/ajpheart.00723.2004. Estrogen receptor- mediates male-female differences in the development of pressure
More informationPOSTDOCTORAL TRAINING
2 Curriculum Vitae JULIAN E. STELZER, PhD CONTACT DETAILS Phone: 216-368-8636 julian.stelzer@case.edu EDUCATION 1992-96 McGill University, Montréal, Canada BS, Physiology. 1996-98 University of Saskatchewan,
More informationVentricular Interactions in the Normal and Failing Heart
Ventricular Interactions in the Normal and Failing Heart Congenital Cardiac Anesthesia Society 2015 Pressure-volume relations Matched Left ventricle to low hydraulic impedance Maximal stroke work limited
More informationSUPPLEMENTAL DATA. Lumen area ( m 2 )
Elastin Lumen area ( m 2 ) Media to lumen ratio (x1) H.E. Medium thickness ( m) Medium area ( m 2 ) SUPPLEMENTAL DATA A (Bmal1 flox/flox ) (SM-Bmal1 -/- ) B 1 8 8 6 6 4 4 2 2 1µm 5 8 4 6 3 2 4 1 2 Supplemental
More informationAtrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands
Atrial fibrillation and stroke Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January 2018 Content Stroke what is the problem for patients with AF?
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature10188 Supplementary Figure 1. Embryonic epicardial genes are down-regulated from midgestation stages and barely detectable post-natally. Real time qrt-pcr revealed a significant down-regulation
More informationGrowth and Differentiation Phosphorylation Sampler Kit
Growth and Differentiation Phosphorylation Sampler Kit E 0 5 1 0 1 4 Kits Includes Cat. Quantity Application Reactivity Source Akt (Phospho-Ser473) E011054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit
More informationSelected age-associated changes in the cardiovascular system
Selected age-associated changes in the cardiovascular system Tamara Harris, M.D., M.S. Chief, Interdisciplinary Studies of Aging Acting Co-Chief, Laboratory of Epidemiology and Population Sciences Intramural
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationThe Cardiovascular System and Aging- Is it Built to Fail?
The Cardiovascular System and Aging- Is it Built to Fail? Francis G. Spinale, MD, PhD Professor of Surgery and Cell Biology and Anatomy University of South Carolina School of Medicine Veterans Affairs
More informationPeroxisome proliferator-activated receptor- (PPAR- ) is
Endothelin-1 Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator Activated Receptor- Partly Via Blockade of c-jun NH 2 -Terminal Kinase Pathway Yoko Irukayama-Tomobe, PhD;
More informationLarge myocardial infarction (MI) is a major cause of
Beneficial Effects of Long-Term Use of the Antioxidant Probucol in Heart Failure in the Rat Ying Tung Sia, MSc; Nathalie Lapointe, MSc; Thomas G. Parker, MD; James N. Tsoporis, PhD; Christian F. Deschepper,
More informationA Comparative Analysis of Capillary Density in the Myocardium of Normotensive and Spontaneously Hypertensive Rats
Institute of Experimental Morphology, Pathology and Anthropology with Museum Bulgarian Anatomical Society Acta morphologica et anthropologica, 24 (1-2) Sofia 2017 A Comparative Analysis of Capillary Density
More informationDilated cardiomyopathy (DCM) represents a common
Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy Edith K. Podewski, MD; Denise Hilfiker-Kleiner, PhD;
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationQualifying Examination (Part I)
Department of Pharmacology Qualifying Examination (Part I) December 12 & 13, 2006 Please remember that this is a closed-book examination. You must be prepared to answer 4 of the 7 questions. Although not
More informationReperfusion Injury: How Can We Reduce It?
MI/CAD: Practical Question in Management of AMI Patients Reperfusion Injury: How Can We Reduce It? Hyun-Jai Cho, M.D., Ph.D Cardiovascular Center & Department of Internal Medicine Seoul National University
More informationMyocardial lipid accumulation and lipotoxicity in heart failure
Myocardial lipid accumulation and lipotoxicity in heart failure P. Christian Schulze, MD, PhD New York - Presbyterian Hospital, Columbia University Medical Center, Division of Cardiology, New York, NY,
More informationMyocardial fibrosis is a pathological feature associated
Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II Induced Hypertension Sahoko Ichihara, MD; Takaaki Senbonmatsu, MD, PhD; Edward
More informationCardiovascular Research Advance Access published August 12, New pathophysiological function of protein phosphatase 2A?
Cardiovascular Research Advance Access published August 12, 2008 1 EDITORIAL New pathophysiological function of protein phosphatase 2A? Joachim Neumann* Institut für Pharmakologie und Toxikologie, Medizinische
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationGallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity
Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity Yuhee Ryu 1,+, Li Jin 1,2+, Hae Jin Kee 1,, Zhe Hao Piao 3, Jae
More informationNabeel R. Obeid Mentors: Erin A. Booth and Dr. Benedict R. Lucchesi
Cardioprotective Action of Selective Estrogen-receptor Agonists against Myocardial Ischemia and Reperfusion Injury Nabeel R. Obeid Mentors: Erin A. Booth and Dr. Benedict R. Lucchesi Abstract Cell death
More informationMolecular Basis of Sex Differences in Cardiac Hypertrophy and Heart Failure
Eastern Kentucky University Encompass Online Theses and Dissertations Student Scholarship January 2016 Molecular Basis of Sex Differences in Cardiac Hypertrophy and Heart Failure Maya James Eastern Kentucky
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationSupplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained
Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained with MitoTracker (red), then were immunostained with
More informationFOCUS ON CARDIOVASCULAR DISEASE
The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.
More information6. Lochner, A., Tromp, E., Mouton, R. Signal transduction in myocardial ischaemia and reperfusion. Mol Cell Biochem., 160/161: , 1996.
PUBLICATIONS IN PEER-REVIEWED JOURNALS: 1. Moolman, J.A., Genade, S., Tromp, E., Lochner, A. Ischaemic preconditioning: interaction with antiadrenergic interventions. J Mol Cell Cardiol 27(6): A161, June
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationSupplement Material. chain (MLC2v) promoter to generate cardiac-specific MKK4 knockout mice (referred to
Supplement Material Materials and Methods Generation of MKK Mutant Mice The mkk-flox mice (referred to as ) were previously generated and characterised. mice were mated with mice expressing Cre under a
More informationBiol403 MAP kinase signalling
Biol403 MAP kinase signalling The mitogen activated protein kinase (MAPK) pathway is a signalling cascade activated by a diverse range of effectors. The cascade regulates many cellular activities including
More informationMedical Policy and and and and
ARBenefits Approval: 10/12/2011 Effective Date: 01/01/2012 Revision Date: Code(s): 93799, Unlisted cardiovascular service or procedure Medical Policy Title: Percutaneous Transluminal Septal Myocardial
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationשינויים מולקולאריים ומבניים באי ספיקת לב אפשרויות לטיפול עתידני
שינויים מולקולאריים ומבניים באי ספיקת לב אפשרויות לטיפול עתידני פרופ יהונתן ליאור 1 Braunwald s Heart Disease 8th Edition Chapter 21 Mechanisms of Cardiac Contraction and Relaxation Chapter 22 Pathophysiology
More informationEffects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation
J Cardiol 2001 ; 37: 27 33 Effects of Cilostazol in Patients With Bradycardiac Atrial Fibrillation 1 2 1 Masato Kouki KISHIDA, MD WATANABE, MD Abstract Objectives. Cilostazol, an antithrombotic agent,
More information-adrenergic receptor subtypes blockade on the rat myocardium inotropy
Research Article The effect of -adrenergic receptor subtypes blockade on the rat myocardium inotropy Insaf Ilkhamovich Khabibrakhmanov*, Nafisa Ilgizovna Ziшatdinova, Timur Lvovich Zefirov ABSTRACT Aim:
More informationSUPPLEMENTARY INFORMATION
Figure S1 Treatment with both Sema6D and Plexin-A1 sirnas induces the phenotype essentially identical to that induced by treatment with Sema6D sirna alone or Plexin-A1 sirna alone. (a,b) The cardiac tube
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationUp-Regulation of Phosphorylated ATM/ATR Substrate/Akt Expression by Phenylephrine in Peri-Infarct Myocardium in Rats
Original Article??? Acta Cardiol Sin 2011;27:182 8 Basic Science Up-Regulation of Phosphorylated ATM/ATR Substrate/Akt Expression by Phenylephrine in Peri-Infarct Myocardium in Rats Yang Mu, 1,2 Gang Li,
More informationDivision of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan 3
Suppressor of cytokine signaling-3 is a biomechanical stress inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways Hideo Yasukawa, 1 Masahiko Hoshijima, 1 Yusu
More information(Stratagene, La Jolla, CA) (Supplemental Fig. 1A). A 5.4-kb EcoRI fragment
SUPPLEMENTAL INFORMATION Supplemental Methods Generation of RyR2-S2808D Mice Murine genomic RyR2 clones were isolated from a 129/SvEvTacfBR λ-phage library (Stratagene, La Jolla, CA) (Supplemental Fig.
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationThe Effects of Ovarian Hormones and Exercise on Gene Markers of Cardiac Dysfunction
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses Dissertations and Theses 2015 The Effects of Ovarian Hormones and Exercise on Gene Markers of Cardiac Dysfunction Anisha S.
More informationPrevious experimental evidence indicates that some cardiovascular
Report Downloaded from http://circres.ahajournals.org/ by guest on July 1, 2018 Autocrine Stimulation of Cardiac Na -Ca 2 Exchanger Currents by Endogenous Endothelin Released by Angiotensin II Ernesto
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationOn Line Data Supplement
On Line Data Supplement Chemicals and Other Materials [γ- 32 P]ATP, L-[ 35 S]methionine, L-[ 3 H]leucine, m 7 GTP-Sepharose, glutathione- Sepharose 4B and ECL reagents were purchased from Amersham Pharmacia
More informationHeart failure is increasing in prevalence and is a debilitating
Tumor Suppressor A2 Protects Against Cardiac Hypertrophy and Fibrosis by Blocking Transforming Growth Factor- Activated Kinase 1 Dependent Signaling He Huang, Qi-Zhu Tang, Ai-Bing Wang, Manyin Chen, Ling
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More informationGenetic ablation of Acp1 (Lmptp) in mice prevents heart failure
Genetic ablation of Acp1 (Lmptp) in mice prevents heart failure Coralie Poizat, Ph.D. Director, Cardiovascular Research Program KFSHRC-Riyadh Saudi Heart Failure Working Group Jeddah, 5 December 2015 Cardiovascular
More informationHuman cardiac hypertrophy often develops as a by-product
Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure Overload Ian S. Harris, MD; Shaosong Zhang, MD, PhD; Ilya Treskov, BS; Attila Kovacs, MD; Carla Weinheimer,
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationChanges in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease
...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic
More informationWhat is new in hypertensi n? MARIA ROJAS, MD MPH Mount Baker Nephrology September
What is new in hypertensi n? MARIA ROJAS, MD MPH Mount Baker Nephrology September 18 2015 Nothing to disclose except. Topics for discussion Background info Hypertension in the elderly Rationale for new
More informationSUPPLEMENTARY FIG. S5. ROS regulated the signaling responses of A. gambiae 4a3B cells to human insulin. (A) 4a3B cells were stimulated with 6000
Supplementary Data SUPPLEMENTARY FIG. S1. Exogenous H 2 O 2 induced rapid activation of ERK in Anopheles stephensi cells. ASE cells were treated with PBS or with 500 mmh 2 O 2 for 5, 30, 60, and 180 min.
More informationFetal gene upregulation by 1-wk TAC is significantly increased in mice lacking RGS2.
3562-RG-1 Supplementary Figure 1 Fetal gene upregulation by 1-wk is significantly increased in mice lacking RGS2. ANP(Nppa) /BNP(Nppb) A-type and B-type natriuretic peptide; β-mhc (Myh7) beta myosin heavy
More informationIndex. A Action potential duration, increased, by decreases in sodium current,
Heart Failure Clin 1 (2005) 313 319 Index Note: Page numbers of article titles are in boldface type. A Action potential duration, increased, by decreases in sodium current, 201 202 Adenylyl cyclase, overexpression
More information